ICICI Prudential Launches Nifty Pharma ETF: NFO, Dates And Key Details

ICICI Prudential Mutual Fund is set to launch the ICICI Prudential Nifty Pharma ETF, with the New Fund Offer (NFO) opening on October 12, 2026 and closing on October 19, 2026. The open-ended exchange-traded fund will track the Nifty Pharma Index, giving investors exposure to a basket of pharmaceutical companies through a single ETF. The minimum investment during the NFO is Rs 1,000, with further investments allowed in multiples of Re 1.

ETF To Offer Exposure To Pharma Stocks

The Nifty Pharma Index comprises companies operating across India's pharmaceutical industry, covering businesses involved in areas such as formulations, generics, speciality medicines and other healthcare products. The index provides exposure across companies of different sizes rather than depending on a single pharmaceutical stock.

As of September 30, 2026, Sun Pharmaceutical Industries was the largest constituent of the index, followed by Divi's Laboratories, Lupin, Cipla and Dr Reddy's Laboratories. The portfolio had 46.33 per cent allocated to Large-Cap companies, while mid- and Small-Cap companies accounted for 53.67 per cent.

Why India's Pharma Sector Remains In Focus

India has become one of the world's major pharmaceutical manufacturing hubs. The country is the third-largest pharmaceutical producer by volume and supplies roughly 20 per cent of global generic medicines by volume. Its strengths extend across generic medicines, formulations, chemistry and the supply of affordable healthcare products.

The Indian pharmaceutical market is currently estimated at around USD 60 billion and is projected to reach USD 80 billion by 2031. Domestic demand has also remained strong, with the pharmaceutical market growing 13.5 per cent year-on-year in June 2026. Growing demand for specialised medicines and contract development and manufacturing services is adding another layer of opportunity for Indian drugmakers.

Policy Support Adds To The Sector's Outlook

Government initiatives are also supporting the industry's expansion. Programmes such as Biopharma SHAKTI and production-linked incentive schemes are aimed at encouraging investment, strengthening domestic manufacturing and building capabilities in areas such as active pharmaceutical ingredients.

The industry is also moving towards higher-value segments, including complex generics, injectables, specialty medicines, biologics and contract manufacturing. The growing demand for biosimilars and CDMO services is creating opportunities beyond traditional generic drug manufacturing.

GLP-1 Drugs Could Open Another Opportunity

GLP-1 medicines used for obesity and diabetes have emerged as another area of interest for the pharmaceutical industry. With semaglutide losing patent protection, more manufacturers can potentially enter the market and develop competing products.

For Indian pharmaceutical companies with the required manufacturing capabilities and regulatory approvals, this could create an additional opportunity in two large therapeutic areas.

Nifty Pharma Index Has Delivered Positive Returns

The Nifty Pharma Index has delivered positive rolling returns over recent periods. Data as of September 30, 2026 shows one-year rolling returns of around 11 per cent, while two-, three-, four- and five-year rolling returns were around 9 per cent annually. The index gained 18 per cent on a year-to-date basis.

With the NFO opening on October 12, investors will have another exchange-traded option to gain diversified exposure to India's pharmaceutical sector. However, as with any sector-focused investment, returns will remain linked to the performance and valuation of the underlying pharma companies.

Disclaimer: This article is for informational purposes only and not investment advice.